IBDEI1UV ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,32665,2)
 ;;=^5001925
 ;;^UTILITY(U,$J,358.3,32666,0)
 ;;=C91.11^^182^1992^42
 ;;^UTILITY(U,$J,358.3,32666,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32666,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,32666,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,32666,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,32667,0)
 ;;=C91.10^^182^1992^43
 ;;^UTILITY(U,$J,358.3,32667,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32667,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,32667,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,32667,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,32668,0)
 ;;=C92.11^^182^1992^44
 ;;^UTILITY(U,$J,358.3,32668,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32668,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
 ;;^UTILITY(U,$J,358.3,32668,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,32668,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,32669,0)
 ;;=C92.10^^182^1992^45
 ;;^UTILITY(U,$J,358.3,32669,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32669,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
 ;;^UTILITY(U,$J,358.3,32669,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,32669,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,32670,0)
 ;;=D47.1^^182^1992^46
 ;;^UTILITY(U,$J,358.3,32670,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32670,1,3,0)
 ;;=3^Chronic Myeloproliferative Disease
 ;;^UTILITY(U,$J,358.3,32670,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,32670,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,32671,0)
 ;;=C82.69^^182^1992^47
 ;;^UTILITY(U,$J,358.3,32671,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32671,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,32671,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,32671,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,32672,0)
 ;;=C82.60^^182^1992^48
 ;;^UTILITY(U,$J,358.3,32672,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32672,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,32672,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,32672,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,32673,0)
 ;;=D56.2^^182^1992^49
 ;;^UTILITY(U,$J,358.3,32673,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32673,1,3,0)
 ;;=3^Delta-Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,32673,1,4,0)
 ;;=4^D56.2
 ;;^UTILITY(U,$J,358.3,32673,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,32674,0)
 ;;=D75.9^^182^1992^50
 ;;^UTILITY(U,$J,358.3,32674,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32674,1,3,0)
 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
 ;;^UTILITY(U,$J,358.3,32674,1,4,0)
 ;;=4^D75.9
 ;;^UTILITY(U,$J,358.3,32674,2)
 ;;=^5002393
 ;;^UTILITY(U,$J,358.3,32675,0)
 ;;=D59.0^^182^1992^53
 ;;^UTILITY(U,$J,358.3,32675,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32675,1,3,0)
 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,32675,1,4,0)
 ;;=4^D59.0
 ;;^UTILITY(U,$J,358.3,32675,2)
 ;;=^5002323
 ;;^UTILITY(U,$J,358.3,32676,0)
 ;;=D59.2^^182^1992^54
 ;;^UTILITY(U,$J,358.3,32676,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32676,1,3,0)
 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,32676,1,4,0)
 ;;=4^D59.2
 ;;^UTILITY(U,$J,358.3,32676,2)
 ;;=^5002325
 ;;^UTILITY(U,$J,358.3,32677,0)
 ;;=R59.9^^182^1992^57
 ;;^UTILITY(U,$J,358.3,32677,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32677,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Unspec
 ;;^UTILITY(U,$J,358.3,32677,1,4,0)
 ;;=4^R59.9
 ;;^UTILITY(U,$J,358.3,32677,2)
 ;;=^5019531
 ;;^UTILITY(U,$J,358.3,32678,0)
 ;;=D47.3^^182^1992^58
 ;;
 ;;$END ROU IBDEI1UV
